UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2017	Oct. 31, 2016
Operating revenue:
Personalized oncology solutions	$ 378,000	$ 497,000	$ 818,000	$ 1,007,000
Translational oncology solutions	4,825,000	3,960,000	9,419,000	7,119,000
Total operating revenue	5,203,000	4,457,000	10,237,000	8,126,000
Costs and operating expenses:
Cost of personalized oncology solutions	259,000	374,000	646,000	847,000
Cost of translational oncology solutions	2,394,000	1,829,000	4,648,000	3,879,000
Research and development	1,115,000	1,008,000	2,233,000	2,219,000
Sales and marketing	551,000	717,000	1,235,000	1,643,000
General and administrative	954,000	1,022,000	2,164,000	2,555,000
Total costs and operating expenses	5,273,000	4,950,000	10,926,000	11,143,000
Loss from operations	(70,000)	(493,000)	(689,000)	(3,017,000)
Other (expense):
Other (expense)	(13,000)	(16,000)	(64,000)	(25,000)
Total other (expense)	(13,000)	(16,000)	(64,000)	(25,000)
Loss before provision for income taxes	(83,000)	(509,000)	(753,000)	(3,042,000)
Provision for (Benefit from) income taxes	11,000	(5,000)	15,000	9,000
Net loss	$ (94,318)	$ (504,000)	$ (768,475)	$ (3,051,000)
Net loss per common share outstanding
Net loss per common share outstanding, basic and diluted (in dollars per share)	$ (0.01)	$ (0.05)	$ (0.07)	$ (0.32)
Weighted average common shares outstanding
Weighted average common shares outstanding, basic and diluted (in shares)	10,988,321	10,967,491	10,984,703	9,560,088